PREMIER BIOMEDICAL, INC. (OTCMKTS:BIEI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Departure of Directors or Certain Officers; Election of Direcdtors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective on May 22, 2020, David Caplan was appointed to our Board of Directors, to serve until his successor is appointed or until our next annual meeting of shareholders. There are no arrangements or understandings between Mr. Caplan and any other person to which Mr. Caplan was selected as a director. Mr. Caplan is not anticipated to sit on any particular board committees.

About PREMIER BIOMEDICAL, INC. (OTCMKTS:BIEI)

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically focusing the treatment of Cancer, Multiple Sclerosis (MS), Neuropathic Pain, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig’s Disease), Fibromyalgia, Traumatic Brain Injury (TBI), Alzheimer’s disease (AD), and Blood Sepsis and Viremia. The Company intends to develop its Sequential-Dialysis Technique, to target Cancer, Alzheimer’s disease, ALS, Blood Sepsis, Leukemia and other life-threatening cancers. The Sequential-Dialysis Technique is a methodology for the removal of those molecules, which are harmful and responsible for causing diseases. Its Sequential-Dialysis Technique method removes those excitatory neural transmitters that cause the death of those cells. It also intends to develop Feldetrex, a candidate drug, for the treatment of MS, Fibromyalgia and TBI. Feldetrex utilizes a low dosage of Naltrexone to increase endogenous enkephalins10.